Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Traykovska

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Antibiotics (Basel, Switzerland)|November 24, 2022
Targeting SAM-I Riboswitch Using Antisense Oligonucleotide Technology for Inhibiting the Growth of <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i>Martina Traykovska, Robert Penchovsky
ACS Synthetic Biology|April 20, 2022
Engineering Antisense Oligonucleotides as Antibacterial Agents That Target FMN Riboswitches and Inhibit the Growth of <i>Staphylococcus aureus</i>, <i>Listeria monocytogenes</i>, and <i>Escherichia coli</i>Martina Traykovska, Robert Penchovsky
Expert Opinion on Drug Discovery|May 19, 2015
Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?Robert Penchovsky, Martina Traykovska
Antibiotics (Basel, Switzerland)|November 24, 2023
Targeting FMN, TPP, SAM-I, and glmS Riboswitches with Chimeric Antisense Oligonucleotides for Completely Rational Antibacterial Drug DevelopmentNikolet Pavlova, Martina Traykovska, Robert Penchovsky
Molecules (Basel, Switzerland)|August 28, 2025
Targeting Bacterial Adenylate Kinase mRNA with a Chimeric Antisense Oligonucleotide for Rational Antibacterial Drug DevelopmentLozena A Otcheva, Martina Traykovska, Robert Penchovsky
ACS Synthetic Biology|November 4, 2021
Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug DevelopmentMartina Traykovska, Katya B Popova, Robert Penchovsky
ACS Applied Bio Materials|September 28, 2022
Targeting TPP Riboswitches Using Chimeric Antisense Oligonucleotide Technology for Antibacterial Drug DevelopmentMartina Traykovska, Lozena A Otcheva, Robert Penchovsky
Antibiotics (Basel, Switzerland)|March 27, 2024
Antisense and Functional Nucleic Acids in Rational Drug DevelopmentRobert Penchovsky, Antoniya V Georgieva, Vanya Dyakova, et al.
ACS Infectious Diseases|December 18, 2025
Rational Design of Chimeric Antisense Oligonucleotides that Target FMN Riboswitch mRNAs and Inhibit the Growth of Methicillin-Resistant <i>Staphylococcus aureus</i>Vanya N Dyakova, Martina Traykovska, Nikolet Pavlova, et al.
Future Medicinal Chemistry|August 17, 2022
Versatile tools of synthetic biology applied to drug discovery and productionNikolet Pavlova, Georgi Y Miloshev, Antoniya V Georgieva, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Antibiotics (Basel, Switzerland)|November 24, 2022
Targeting SAM-I Riboswitch Using Antisense Oligonucleotide Technology for Inhibiting the Growth of <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i>Martina Traykovska, Robert Penchovsky
ACS Synthetic Biology|April 20, 2022
Engineering Antisense Oligonucleotides as Antibacterial Agents That Target FMN Riboswitches and Inhibit the Growth of <i>Staphylococcus aureus</i>, <i>Listeria monocytogenes</i>, and <i>Escherichia coli</i>Martina Traykovska, Robert Penchovsky
Expert Opinion on Drug Discovery|May 19, 2015
Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?Robert Penchovsky, Martina Traykovska
Antibiotics (Basel, Switzerland)|November 24, 2023
Targeting FMN, TPP, SAM-I, and glmS Riboswitches with Chimeric Antisense Oligonucleotides for Completely Rational Antibacterial Drug DevelopmentNikolet Pavlova, Martina Traykovska, Robert Penchovsky
Molecules (Basel, Switzerland)|August 28, 2025
Targeting Bacterial Adenylate Kinase mRNA with a Chimeric Antisense Oligonucleotide for Rational Antibacterial Drug DevelopmentLozena A Otcheva, Martina Traykovska, Robert Penchovsky
ACS Synthetic Biology|November 4, 2021
Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug DevelopmentMartina Traykovska, Katya B Popova, Robert Penchovsky
ACS Applied Bio Materials|September 28, 2022
Targeting TPP Riboswitches Using Chimeric Antisense Oligonucleotide Technology for Antibacterial Drug DevelopmentMartina Traykovska, Lozena A Otcheva, Robert Penchovsky
Antibiotics (Basel, Switzerland)|March 27, 2024
Antisense and Functional Nucleic Acids in Rational Drug DevelopmentRobert Penchovsky, Antoniya V Georgieva, Vanya Dyakova, et al.
ACS Infectious Diseases|December 18, 2025
Rational Design of Chimeric Antisense Oligonucleotides that Target FMN Riboswitch mRNAs and Inhibit the Growth of Methicillin-Resistant <i>Staphylococcus aureus</i>Vanya N Dyakova, Martina Traykovska, Nikolet Pavlova, et al.
Future Medicinal Chemistry|August 17, 2022
Versatile tools of synthetic biology applied to drug discovery and productionNikolet Pavlova, Georgi Y Miloshev, Antoniya V Georgieva, et al.
Pageof 1